Protalix BioTherapeutics to Hold Fiscal Year 2021 Financial and Business Results Conference Call on March 31, 2022

Firm to host convention simply call and webcast at 8:30 a.m. EDT

CARMIEL, Israel, March 24, 2022 /PRNewswire/ — Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company targeted on the growth, generation and commercialization of recombinant therapeutic proteins made by its proprietary ProCellEx® plant mobile-based protein expression technique, currently announced that it will launch its financial results for fiscal yr 2021 and give a business enterprise update on Thursday, March 31, 2022. The Company’s administration will host a convention connect with to examine the money effects and give a business enterprise update on the latest company and medical developments at 8:30 a.m. Japanese Daylight Price savings Time (EDT).

Protalix Biotherapeutics Logo

Protalix Biotherapeutics Brand

Convention Contact Specifics:

Thursday, March 31, 2022, 8:30 a.m. Japanese Daylight Cost savings Time (EDT)

Domestic: 877-423-9813
International: 201-689-8573
Convention ID: 13727524

Webcast Information:

The conference will be webcast stay from the Firm’s web-site and will be available via the following links:

Firm Hyperlink: https://protalixbiotherapeutics.gcs-website.com/events0

Webcast Connection: Registration – https://tinyurl.com/bdmsa52p

Conference ID: 13727524

Make sure you obtain the internet websites at minimum 15 minutes in advance of the meeting to register, download and set up any important audio software.

The conference simply call will be offered for replay for two weeks on the Events Calendar of the Investors segment of the Firm’s site, at the previously mentioned link.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical business targeted on the development and commercialization of recombinant therapeutic proteins expressed as a result of its proprietary plant mobile-centered expression procedure, ProCellEx. Protalix was the initial enterprise to get U.S. Food stuff and Drug Administration (Food and drug administration) acceptance of a protein created by way of plant cell-primarily based in suspension expression procedure. Protalix’s one of a kind expression program signifies a new technique for acquiring recombinant proteins in an industrial-scale way.

Protalix’s initial product or service created by ProCellEx, taliglucerase alfa, was permitted by the Fda in May possibly 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has accredited to Pfizer Inc. the around the world progress and commercialization legal rights for taliglucerase alfa, excluding Brazil, exactly where Protalix retains total legal rights.

Protalix’s improvement pipeline is made up of proprietary variations of recombinant therapeutic proteins that goal set up pharmaceutical markets, like the pursuing product candidates: pegunigalsidase alfa, a modified stabilized variation of the recombinant human α–Galactosidase–A protein for the procedure of Fabry condition alidornase alfa or PRX–110, for the treatment method of various human respiratory diseases or problems PRX–115, a plant mobile-expressed recombinant PEGylated uricase for the treatment method of refractory gout PRX–119, a plant mobile-expressed extensive action DNase I for the treatment method of NETs-associated diseases and other people. Protalix has partnered with Chiesi Farmaceutici S.p.A., the two in the United States and exterior the United States, for the development and commercialization of pegunigalsidase alfa.

Trader Get hold of

Chuck Padala, Taking care of Director
LifeSci Advisors
646-627-8390
[email protected]

Cision

Cision

Check out first material:https://www.prnewswire.com/information-releases/protalix-biotherapeutics-to-hold-fiscal-year-2021-monetary-and-company-outcomes-meeting-simply call-on-march-31-2022-301509826.html

Resource Protalix BioTherapeutics, Inc.